These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14664228)

  • 1. Perindopril (Coversyl) prevents cardiovascular death and MI in coronary disease patients regardless of their cardiovascular risk.
    Opie L; Dalby T; Naidoo DP
    Cardiovasc J S Afr; 2003; 14(5):277-9. PubMed ID: 14664228
    [No Abstract]   [Full Text] [Related]  

  • 2. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PERSUADE...(a EUROPA sub-study)...results: perindopril protects diabetic patients with coronary disease from cardiovascular death and heart attacks.
    Cardiovasc J S Afr; 2004; 15(3):146. PubMed ID: 15356914
    [No Abstract]   [Full Text] [Related]  

  • 4. Perindopril protects diabetics with coronary disease from cardiovascular death and heart attacks.
    Cardiovasc J S Afr; 2004; 15(2):98. PubMed ID: 15148549
    [No Abstract]   [Full Text] [Related]  

  • 5. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 6. ACE inhibitors: the impact of the EUROPA study on CAD.
    Cardiovasc J S Afr; 2003; 14(4):211-2. PubMed ID: 14619870
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
    Sica DA
    J Clin Hypertens (Greenwich); 2004 Feb; 6(2):91-5. PubMed ID: 14872148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of early perindopril administration on mortality and morbidity in patients with high risk of acute myocardial infarction.
    Protopopescu T; Toporan D; Paraschiv A; Ioan A
    Rom J Intern Med; 1998; 36(3-4):197-205. PubMed ID: 10822516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
    White HD
    Lancet; 2003 Sep; 362(9386):755-7. PubMed ID: 13678865
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving endothelial function and reducing remodeling post-MI are key to perindopril benefits in coronary artery disease.
    Cardiovasc J S Afr; 2006; 17(4):203-4. PubMed ID: 17001425
    [No Abstract]   [Full Text] [Related]  

  • 15. New pathophysiological insights explain life-saving benefits of perindopril in coronary artery disease patients.
    Cardiovasc J S Afr; 2004; 15(5):248-9. PubMed ID: 15483736
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of Coversyl].
    Jacobsen K
    Ugeskr Laeger; 2002 Aug; 164(32):3791; author reply 3791-2. PubMed ID: 12362619
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
    Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Remodeling with angiotensin-converting enzyme inhibitors: from GISSI to PREAMI].
    Nicolosi GL
    Ital Heart J; 2005 Nov; 6 Suppl 7():33S-39S. PubMed ID: 16485515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.